A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)

Trial Profile

A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs OPT 302 (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Opthea
  • Most Recent Events

    • 02 Jul 2018 According to an Opthea media release, the company Clinical Trial Reaches Mid-Way Point of Patient Recruitment, Opthea Recruits 176th Patient and On-Track to Report Primary Data Analysis Early 2020.
    • 27 Mar 2018 According to an Opthea media release, the company conducted The Investigators Meeting European and Israeli Investigators and site staff involved in this trial to review the trial protocol and patient eligibility criteria. The company has Opthea conducted a similar US Investigators Meeting in Dallas Texas in October 2017, prior to initiation of patient enrolment at US sites. Primary analysis of the data from the study is anticipated in early 2020.
    • 27 Mar 2018 According to an Opthea media release, the randomization and dosing of patients in these jurisdictions follows successful regulatory interactions with the each of the participating European countries regulatory agencies via the European Voluntary Harmonisation Process (VHP), the Ministry of Health in Israel and the US Food & Drug Administration (FDA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top